Walgreens Boots Alliance Inc. is poised to revise its agreement to buy individual Rite Aid Corp. stores, hoping the move will be enough to resolve outstanding antitrust concerns and clinch U.S. approval for a deal the companies have been pursuing in different forms for two years, said people familiar with the matter.
Walgreens is in the final stage of negotiations with the Federal Trade Commission about its plan to buy more than 2,000 Rite Aid stores and is set to propose a modified deal that could be announced soon, according to three people, who declined to be identified because the talks are confidential. Rite Aid shares jumped as much as 5.3 percent in New York.
The deal would be a hard-won victory for Walgreens and its Chief Executive Officer Stefano Pessina, who has pushed for a transaction that could clear regulatory approval since the fall of 2015.
The companies and the Federal Trade Commission are close to an agreement that would allow the deal to proceed, said the people, who declined to discuss details of the revised transaction. The number of stores involved in the latest iteration won't change dramatically, one of the people said.
The Federal Trade Commission is nearing the end of its review of Walgreens' plan to buy the Rite Aid locations and must approve the deal or issue a so-called second request seeking more information. A revised filing by Walgreens would head off an in-depth investigation and give the agency an additional 30 days to reach a final decision, though the trade commission could act sooner if it's satisfied the tweaked transaction resolves its concerns.
Rite Aid shares rose 10 cents, or 3.8 percent, to close Monday at $2.73. Walgreens shares rose 10 cents to $82.60.
Walgreens and Rite Aid declined to comment about the negotiations. The Federal Trade Commission didn't respond to a request seeking comment.
A modified deal would mark the fourth attempt by Walgreens to win approval for its plan to dramatically expand its footprint through a transaction with Rite Aid. If successful, it would become the No. 1 pharmacy chain in the U.S. by number of store locations, edging out market leader CVS Health Corp. That would leave Rite Aid a distant No. 3 after the sale of almost half of its roughly 4,500 stores in the U.S.
Walgreens initially planned to buy Rite Aid outright with a takeover announced in October 2015 for $9 a share, or $9.4 billion. That deal ran into roadblocks at the Federal Trade Commission, and in January Walgreens and Rite Aid recut the deal in an attempt to resolve the agency's concerns that the combination of the pharmacy chains would hurt competition.
The revamped merger plan called for selling up to 1,200 Rite Aid locations to another buyer to satisfy the trade commission and was worth at least $2 billion less to Rite Aid shareholders.
That approach, which could have cost Walgreens as much as $7.37 billion, again failed to win over the regulator, and Walgreens terminated its second takeover plan in June. The company said it instead would pay $5.18 billion to acquire 2,186 stores, leaving a slimmed-down Rite Aid as a stand-alone company.
Business on 09/19/2017